60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tickborne, potentially life-threatening illness Case studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunos ...